scholarly journals Clinical Pharmacokinetics of Amikacin in Pediatric Patients: A Comprehensive Review of Population Pharmacokinetic Analyses

2018 ◽  
Vol 57 (10) ◽  
pp. 1217-1228 ◽  
Author(s):  
Sílvia M. Illamola ◽  
Catherine M. Sherwin ◽  
J. G. Coen van Hasselt
Keyword(s):  
Pediatric Patients ◽  
Population Pharmacokinetic ◽  
Clinical Pharmacokinetics ◽  
Comprehensive Review

scholarly journals Clinical Pharmacokinetics of Valproic Acid in Pediatric Patients Taking Long Active Tablets. Estimation of Population Pharmacokinetic Parameters.

1994 ◽  
Vol 20 (3) ◽  
pp. 179-184
Author(s):  
HIROMITSU NAKASA ◽  
JUN MARUYAMA ◽  
SHIGERU OHMORI ◽  
TADAAKI RIKIHISA ◽  
KIMIKO MIYANAGA ◽  
...  
Keyword(s):  
Valproic Acid ◽  
Pediatric Patients ◽  
Pharmacokinetic Parameters ◽  
Population Pharmacokinetic ◽  
Clinical Pharmacokinetics

scholarly journals Clinical Pharmacokinetics of Triazoles in Pediatric Patients

2021 ◽  
Author(s):  
Didi Bury ◽  
Wim J. E. Tissing ◽  
Eline W. Muilwijk ◽  
Tom F. W. Wolfs ◽  
Roger J. Brüggemann
Keyword(s):  
Pediatric Patients ◽  
Clinical Pharmacokinetics

scholarly journals Model-Informed Optimization of a Pediatric Clinical Pharmacokinetic Trial of a New Spironolactone Liquid Formulation

Pharmaceutics ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 849
Author(s):  
Manasa Tatipalli ◽  
Vijay Kumar Siripuram ◽  
Tao Long ◽  
Diana Shuster ◽  
Galina Bernstein ◽  
...  
Keyword(s):  
Pharmacokinetic Model ◽  
Allometric Scaling ◽  
Pediatric Patients ◽  
Reference Product ◽  
Population Pharmacokinetic ◽  
Liquid Formulation ◽  
Sampling Schemes ◽  
Quantitative Pharmacology ◽  
Using Data ◽  
Drug Pharmacokinetics

Quantitative pharmacology brings important advantages in the design and conduct of pediatric clinical trials. Herein, we demonstrate the application of a model-based approach to select doses and pharmacokinetic sampling scenarios for the clinical evaluation of a novel oral suspension of spironolactone in pediatric patients with edema. A population pharmacokinetic model was developed and qualified for spironolactone and its metabolite, canrenone, using data from adults and bridged to pediatrics (2 to <17 years old) using allometric scaling. The model was then used via simulation to explore different dosing and sampling scenarios. Doses of 0.5 and 1.5 mg/kg led to target exposures (i.e., similar to 25 and 100 mg of the reference product in adults) in all the reference pediatric ages (i.e., 2, 6, 12 and 17 years). Additionally, two different sampling scenarios were delineated to accommodate patients into sparse sampling schemes informative to characterize drug pharmacokinetics while minimizing phlebotomy and burden to participating children.

Extensive Extraneural Metastases of Cerebral Glioblastoma in a Pediatric Patient: An Extreme Case Report and Comprehensive Review of the Literature

2021 ◽  
pp. 1-6
Author(s):  
Kadir Oktay ◽  
Dogu Cihan Yildirim ◽  
Arbil Acikalin ◽  
Kerem Mazhar Ozsoy ◽  
Nuri Eralp Cetinalp ◽  
...  
Keyword(s):  
Case Report ◽  
Pediatric Patients ◽  
Extreme Case ◽  
Rare Condition ◽  
Review Of The Literature ◽  
Pertinent Literature ◽  
Cervical Lymph Nodes ◽  
Case Presentation ◽  
Comprehensive Review ◽  
Extraneural Metastases

<b><i>Introduction:</i></b> Extraneural metastases of glioblastoma are very rare clinical entities, especially in pediatric patients. Because of their rarity, they can be confused with other pathological processes. <b><i>Case Presentation:</i></b> We report a case of 16-year-old boy with extensive extraneural metastases of glioblastoma. Lung, liver, cervical lymph nodes, skin, and bone metastases were detected in the patient. <b><i>Conclusion:</i></b> We describe the presentation, evaluation, and diagnosis of this rare condition with regard to pertinent literature.

Population Pharmacokinetic and Exposure–Response Analyses of Prasugrel in Pediatric Patients with Sickle Cell Anemia

2017 ◽  
Vol 57 (2) ◽  
pp. 243-254 ◽  
Author(s):  
Brian A. Moser ◽  
Elizabeth S. LaBell ◽  
Emmanuel Chigutsa ◽  
Joseph A. Jakubowski ◽  
David S. Small
Keyword(s):  
Sickle Cell ◽  
Sickle Cell Anemia ◽  
Pediatric Patients ◽  
Population Pharmacokinetic ◽  
Exposure Response

scholarly journals Anesthetic Agents in Pediatric Patients, A Comprehensive Review of Pharmacological Considerations in Clinical Practice

2020 ◽  
Vol 8 (4) ◽  
Author(s):  
Alan Kaye ◽  
George Jeha ◽  
Jordan Renschler ◽  
Mitchell Fuller ◽  
Alex Pham ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Pediatric Patients ◽  
Comprehensive Review ◽  
Anesthetic Agents

Clinical Pharmacokinetics of Irinotecan and Its Metabolites: A Population Analysis

2002 ◽  
Vol 20 (15) ◽  
pp. 3293-3301 ◽  
Author(s):  
Rujia Xie ◽  
Ron H.J. Mathijssen ◽  
Alex Sparreboom ◽  
Jaap Verweij ◽  
Mats O. Karlsson
Keyword(s):  
Tissue Distribution ◽  
Goodness Of Fit ◽  
Population Analysis ◽  
Dose Range ◽  
Central Compartment ◽  
Volume Of Distribution ◽  
Population Pharmacokinetic ◽  
Clinical Pharmacokinetics ◽  
Lactone Form ◽  
Time Courses

PURPOSE: To build population pharmacokinetic (PK) models for irinotecan (CPT-11) and its currently identified metabolites. PATIENTS AND METHODS: Seventy cancer patients (24 women and 46 men) received 90-minute intravenous infusions of CPT-11 in the dose range of 175 to 300 mg/m2. The PK models were developed to describe plasma concentration profiles of the lactone and carboxylate forms of CPT-11 and 7-ethyl-10-hydroxycamptothecin (SN-38) and the total forms of SN-38 glucuronide (SN-38G), 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]-carbonyloxycamptothecin (APC), and 7-ethyl-10-[4-amino-1-piperidino]-carbonyloxycamptothecin (NPC) by using NONMEM. RESULTS: The interconversion between the lactone and carboxylate forms of CPT-11 was relatively rapid, with an equilibration half-life of 14 minutes in the central compartment and hydrolysis occurring at a rate five times faster than lactonization. The same interconversion also occurred in peripheral compartments. CPT-11 lactone had extensive tissue distribution (steady-state volume of distribution [Vss], 445 L) compared with the carboxylate form (Vss, 78 L, excluding peripherally formed CPT-11 carboxylate). Clearance (CL) was higher for the lactone form (74.3 L/h) compared with the carboxylate form (12.3 L/h). During metabolite data modeling, goodness of fit indicated a preference of SN-38 and NPC to be formed out of the lactone form of CPT-11, whereas APC could be modeled best by presuming formation from CPT-11 carboxylate. The interconversion between SN-38 lactone and carboxylate was slower than that of CPT-11, with the lactone form dominating at equilibrium. The CLs for SN-38 lactone and carboxylate were similar, but the lactone form had more extensive tissue distribution. CONCLUSION: Plasma data of CPT-11 and metabolites could be adequately described by this compartmental model, which may be useful in predicting the time courses, including interindividual variability, of all characterized substances after intravenous administrations of CPT-11.

Sign in / Sign up

Export Citation Format

Share Document